Evidence map›Paper›PMID 38965349›Full record

ArticleScientific reports2024

An in-vivo treatment monitoring system for ion-beam radiotherapy based on 28 Timepix3 detectors.

Laurent Kelleter, Lukas Marek, Gernot Echner, Pamela Ochoa-Parra, Marcus Winter, Semi Harrabi, Jan Jakubek, Oliver Jäkel, Jürgen Debus, Maria Martisikova

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. The Role of Molecular Imaging in Ion Beam Therapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laurent KelleterHeidelberg Institute for Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany. laurent.kelleter@dkfz.de.
Lukas MarekADVACAM s.r.o., Prague, Czech Republic.
Gernot EchnerHeidelberg Institute for Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Pamela Ochoa-ParraHeidelberg Institute for Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Marcus WinterHeidelberg Ion-Beam Therapy Centre (HIT), Department of Radiation Oncology Heidelberg University Hospital, Heidelberg, Germany.
Semi HarrabiDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Jan JakubekADVACAM s.r.o., Prague, Czech Republic.
Oliver JäkelHeidelberg Institute for Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
Jürgen DebusDivision of Medical Physics in Radiation Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Maria MartisikovaHeidelberg Institute for Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.

Funding

Deutsches Krebsforschungszentrum International PhD programNational Center for Tumor Diseases (NCT Heidelberg) Internal ID
6 · The paper itself

Abstract

Ion-beam radiotherapy is an advanced cancer treatment modality offering steep dose gradients and a high biological effectiveness. These gradients make the therapy vulnerable to patient-setup and anatomical changes between treatment fractions, which may go unnoticed. Charged fragments from nuclear interactions of the ion beam with the patient tissue may carry information about the treatment quality. Currently, the fragments escape the patient undetected. Inter-fractional in-vivo treatment monitoring based on these charged nuclear fragments could make ion-beam therapy safer and more efficient. We developed an ion-beam monitoring system based on 28 hybrid silicon pixel detectors (Timepix3) to measure the distribution of fragment origins in three dimensions. The system design choices as well as the ion-beam monitoring performance measurements are presented in this manuscript. A spatial resolution of

Indexed as

Phantoms, ImagingHeavy Ion RadiotherapyHumansRadiotherapy DosageCharged nuclear fragmentsIn-vivo monitoringIon-beam therapyTimepix3

Identifiers

PMID38965349
PMCPMC11224389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.